Molecular subtyping in urothelial carcinoma treatment
Cancer Cell · 2024
DOI: 10.1016/j.ccell.2024.11.001 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancer Cell, 2024. Verfasst von Xiaowen Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University …. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
The heterogeneity of urothelial carcinoma (UC) and variable treatment responses poses significant clinical challenges. In this issue of Cancer Cell, Hamidi et al. conducted a multi-omics analysis of 2,803 UC patients from four clinical trials with anti-PD-L1, revealing four transcriptional subtypes. This approach could help tailor therapies for UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: docto…
Zitieren
APA
Wu, X., & Sheng, X. (2024). Molecular subtyping in urothelial carcinoma treatment. Cancer Cell. https://doi.org/10.1016/j.ccell.2024.11.001
Vancouver
Wu X, Sheng X. Molecular subtyping in urothelial carcinoma treatment. Cancer Cell. 2024. doi:10.1016/j.ccell.2024.11.001
BibTeX
@article{Wu2024,
author = {Wu, Xiaowen and Sheng, Xinan},
title = {Molecular subtyping in urothelial carcinoma treatment},
journal = {Cancer Cell},
year = {2024},
doi = {10.1016/j.ccell.2024.11.001}
}
EUVIMED